Schoner W. Endogenous cardiac glycosides, a new class of steroid hormones. Eur J Biochem 2002, 269:2440-2448.
Schoner W., Scheiner-Bobis G. Endogenous cardiac glycosides: hormones using the sodium pump as signal transducer. Semin Nephrol 2005, 25:343-351.
Meyer K., Linde H. Collection of toad venoms and chemistry of toad venom steroids. Venomous animals and their venoms 1971, 521-556. Academic Press, NY. W. Bucherl, E. Buckley (Eds.).
Gonick H.C., Ding Y., Vaziri N.D., Bagrov A.Y., Fedorova O.V. Simultaneous measurement of marinobufagenin, ouabain, and hypertension-associated protein in various disease states. Clin Exp Hypertens 1998, 20:617-627.
Bagrov A.Y., Roukoyatkina N.I., Pinaev A.G., Dmitrieva R.I., Fedorova O.V. Effects of two endogenous Na+, K+-ATPase inhibitors, marinobufagenin and ouabain, on isolated rat aorta. Eur J Pharmacol 1995, 274:151-158.
Krenn B.K.L. Bufadienolides from animal and plant sources. Phytochemistry 1998, 48:1-29.
Steyn P.S., van Heerden F.R. Bufadienolides of plant and animal origin. Nat Prod Rep 1998, 15:397-413.
Xu W., Luo H., Zhang Y., et al. Simultaneous determination of five main active bufadienolides of Chan Su in rat plasma by liquid chromatography tandem mass spectrometry. J Chromatogr B Biomed Appl 2007, 859:157-163.
Zhang Y., Tang X., Liu X., Li F., Lin X. Simultaneous determination of three bufadienolides in rat plasma after intravenous administration of bufadienolides extract by ultra performance liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chim Acta 2008, 610:224-231.
Lichtstein D., Gati I., Babila T., Haver E., Katz U. Effect of salt acclimation on digitalis-like compounds in the toad. Biochim Biophys Acta 1991, 1073:65-68.
Fedorova O.V., Talan M.I., Agalakova N.I., Lakatta E.G., Bagrov A.Y. Endogenous ligand of α1 sodium pump, marinobufagenin, is a novel mediator of sodium chloride-dependent hypertension. Circulation 2002, 105:1122-1127.
Uddin M.N., Allen S.R., Jones R.O., Zawieja D.C., Kuehl T.J. Pathogenesis of pre-eclampsia: marinobufagenin and angiogenic imbalance as biomarkers of the syndrome. Transl Res 2012, 160:99-113.
Fedorova O.V., Bagrov A.Y. Inhibition of Na/K ATPase from rat aorta by two Na/K pump inhibitors, ouabain and marinobufagenin: evidence of interaction with different α-subunit isoforms. Am J Hypertens 1997, 10:929-935.
Hauck C., Frishman W.H. Systemic hypertension: the roles of salt, vascular Na+/K+ ATPase and the endogenous glycosides, ouabain and marinobufagenin. Cardiol Rev 2012, 20:130-138.
Puschett J.B., Agunanne E., Uddin M.N. Marinobufagenin, resibufogenin and preeclampsia. Biochim Biophys Acta 2010, 1802:1246-1253.
Bagrov A.Y., Fedorova O.V., Dmitrieva R.I., et al. Characterization of a urinary bufodienolide Na+, K+-ATPase inhibitor in patients after acute myocardial infarction. Hypertension 1998, 31:1097-1103.
Bagrov A.Y., Fedorova O.V., Dmitriev R.I., French A.W., Anderson D.E. Plasma marinobufagenin-like and ouabain-like immunoreactivity during saline volume expansion in anesthetized dogs. Cardiovasc Res 1996, 31:296-305.
Fedorova O.V., Lakatta E.G., Bagrov A.Y. Endogenous Na, K pump ligands are differentially regulated during acute NaCl loading of Dahl rats. Circulation 2000, 102:3009-3014.
Orosz D.E., Hopfer U. Pathophysiological consequences of changes in the coupling ratio of Na, K-ATPase for renal sodium reabsorption and its implications for hypertension. Hypertension 1996, 27:219-227.
Agunanne E., Horvat D., Harrison R., et al. Marinobufagenin levels in preeclamptic patients: a preliminary report. Am J Perinatol 2011, 28:509-514.
Vu H.V., Ianosi-Irimie M.R., Pridjian C.A., et al. Involvement of marinobufagenin in a rat model of human preeclampsia. Am J Nephrol 2005, 25:520-528.
Fedorova O.V., Simbirtsev A.S., Kolodkin N.I., et al. Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension. J Hypertens 2008, 26:2414-2425.
Hilton P.J., White R.W., Lord G.A., et al. An inhibitor of the sodium pump obtained from human placenta. Lancet 1996, 348:303-305.
Dmitrieva R.I., Bagrov A.Y., Lalli E., Sassone-Corsi P., Stocco D.M., Doris P.A. Mammalian bufadienolide is synthesized from cholesterol in the adrenal cortex by a pathway that is independent of cholesterol side-chain cleavage. Hypertension 2000, 36:442-448.
Cunha Filho G.A., Schwartz C.A., Resck I.S., et al. Antimicrobial activity of the bufadienolides marinobufagin and telocinobufagin isolated as major components from skin secretion of the toad Bufo rubescens. Toxicon 2005, 45:777-782.
Clarke B.T. The natural history of amphibian skin secretions, their normal functioning and potential medical applications. Biol Rev 1997, 72:365-379.
Shimada K., Nambara T. Isolation and characterization of cardiotonic steroid conjugates from the skin of Bufo marinus (L.) Schneider. Chem Pharm Bull 1979, 27:1881-1886.
Matsukawa M., Akizawa T., Ohigashi M., Morris J.F., Butler V.P., Yoshioka M. A novel bufadienolide, marinosin, in the skin of the giant toad, Bufo marinus. Chem Pharm Bull 1997, 45:249-254.
Lim T.H., Leitch I.M., Boura A.L.A., Read M.A., Walters W.A.W. Effects of Bufo marinus skin toxins on human fetal extracorporeal blood vessels. Toxicon 1997, 35:293-304.
Ye M., Guo D.-a. Analysis of bufadienolides in the Chinese drug ChanSu by high-performance liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2005, 19:1881-1892.
Hu Y., Yu Z., Yang Z.J., Zhu G., Fong W. Comprehensive chemical analysis of Venenum Bufonis by using liquid chromatography/electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal 2011, 56:210-220.
Ye M., Guo H., Guo H., Han J., Guo D. Simultaneous determination of cytotoxic bufadienolides in the Chinese medicine ChanSu by high-performance liquid chromatography coupled with photodiode array and mass spectrometry detections. J Chromatogr B Biomed Appl 2006, 838:86-95.
Zhang P., Cui Z., Liu Y., Wang D., Liu N., Yoshikawa M. Quality evaluation of traditional Chinese drug toad venom from different origins through a simultaneous determination of bufogenins and indole alkaloids by HPLC. Chem Pharm Bull 2005, 53:1582-1586.
Kamano Y., Pettit G. Synthesis of marinobufagin and marinobufotoxin from telecinobufagin. Cell Mol Life Sci 1972, 28:768.
Pettit G.R., Kamano Y. Steroids and related natural products. 87. Bufadienolides. 28. Marinobufotoxin. J Org Chem 1974, 39:3003-3006.
Cao Y., Song Y., An N., et al. The effects of telocinobufagin isolated from Chan Su on the activation and cytokine secretion of immunocytes in vitro. Fundam Clin Pharmacol 2009, 23:457-464.
Komiyama Y., Dong X.H., Nishimura N., et al. A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patients with terminal renal failure. Clin Biochem 2005, 38:36-45.
Robien W., Kopp B., Schabl D., Schwarz H. Carbon-13 NMR spectroscopy of cardenolides and bufadienolides. Prog Nucl Magn Reson Spectrosc 1987, 19:131-181.
Brown P., Kamano Y., Pettit G.R. High resolution mass spectrometry. Bufadienolides-II. Org Mass Spectrom 1972, 6:613-646.
Gao H., Zehl M., Leitner A., Wu X., Wang Z., Kopp B. Comparison of toad venoms from different Bufo species by HPLC and LC-DAD-MS/MS. J Ethnopharmacol 2010, 131:368-376.
Hayes R.A., Piggott A.M., Dalle K., Capon R.J. Microbial biotransformation as a source of chemical diversity in cane toad steroid toxins. Bioorg Med Chem Lett 2009, 19:1790-1792.
Shimada K., Miyashiro Y., Nishio T. Characterization of in vitro metabolites of toad venom using high-performance liquid chromatography and liquid chromatography-mass spectrometry. Biomed Chromatogr 2006, 20:1321-1327.
Xia X., Jin H., Yan S., Zhang W. Analysis of the bioactive constituents of ChanSu in rat plasma by high performance liquid chromatography with mass spectrometric detection. J Pharm Biomed Anal 2010, 53:646-654.
Adair D., Hinshaw A., Russell G., Rose J., Veille J., Buckalew V. Effects of Fab digoxin-specific antibody (Fab) on mean arterial pressure (MAP) in severe preeclampsia (PE). Am J Hypertens 1997, 10:11A.
Pullen M.A., Brooks D.P., Edwards R.M. Characterization of the neutralizing activity of digoxin-specific Fab toward ouabain-like steroids. J Pharmacol Exp Ther 2004, 310:319-325.
Abi-Ghanem D., Lai X., Berghman L., et al. A chemifluorescent immunoassay for the determination of marinobufagenin in body fluids. J Immunoassay Immunochem 2011, 32:31-46.
Horvat D., Severson J., Uddin M.N., Mitchell B., Puschett J.B. Resibufogenin prevents the manifestations of preeclampsia in an animal model of the syndrome. Hypertens Pregnancy 2010, 29:1-9.
Fedorova O.V., Kolodkin N.I., Agalakova N.I., et al. Antibody to marinobufagenin lowers blood pressure in pregnant rats on a high NaCl intake. J Hypertens 2005, 23:835-842.
